KR20200031663A - 칸나비노이드 유사체 공액체를 포함하는 조성물 및 사용 방법 - Google Patents

칸나비노이드 유사체 공액체를 포함하는 조성물 및 사용 방법 Download PDF

Info

Publication number
KR20200031663A
KR20200031663A KR1020207004617A KR20207004617A KR20200031663A KR 20200031663 A KR20200031663 A KR 20200031663A KR 1020207004617 A KR1020207004617 A KR 1020207004617A KR 20207004617 A KR20207004617 A KR 20207004617A KR 20200031663 A KR20200031663 A KR 20200031663A
Authority
KR
South Korea
Prior art keywords
cannabinoid
composition
chelator
medical
viability
Prior art date
Application number
KR1020207004617A
Other languages
English (en)
Korean (ko)
Inventor
제리 엘. 쥬니어 브라이언트
데이빗 제이. 양
자나 라우볼포바
토리 스트롱
Original Assignee
비리팜 엔터프라이즈 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 비리팜 엔터프라이즈 엘엘씨 filed Critical 비리팜 엔터프라이즈 엘엘씨
Publication of KR20200031663A publication Critical patent/KR20200031663A/ko

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/0412—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K51/0421—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nuclear Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020207004617A 2017-07-18 2018-07-18 칸나비노이드 유사체 공액체를 포함하는 조성물 및 사용 방법 KR20200031663A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762533894P 2017-07-18 2017-07-18
US62/533,894 2017-07-18
PCT/US2018/042707 WO2019018536A1 (en) 2017-07-18 2018-07-18 COMPOSITIONS CONTAINING CONJUGATES OF CANNABINOID ANALOGUES AND METHODS OF USE THEREOF

Publications (1)

Publication Number Publication Date
KR20200031663A true KR20200031663A (ko) 2020-03-24

Family

ID=65016693

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207004617A KR20200031663A (ko) 2017-07-18 2018-07-18 칸나비노이드 유사체 공액체를 포함하는 조성물 및 사용 방법

Country Status (10)

Country Link
EP (1) EP3654971A4 (de)
JP (1) JP2020527589A (de)
KR (1) KR20200031663A (de)
CN (1) CN111065391A (de)
AU (1) AU2018302155B2 (de)
CA (1) CA3070538A1 (de)
EA (1) EA202090116A1 (de)
IL (1) IL272060A (de)
MX (1) MX2020000673A (de)
WO (1) WO2019018536A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3986388A4 (de) * 2019-06-24 2024-02-21 Diverse Biotech, Inc. Cannabinoid-konjugatmoleküle
EP4045023A4 (de) * 2019-10-15 2023-09-13 Diverse Biotech, Inc. Konjugatmoleküle
CN112807301A (zh) * 2020-12-30 2021-05-18 福建省中科生物股份有限公司 麻类植物提取化合物Cannabiorcol在制备抗肿瘤药物上的用途
US11554184B2 (en) 2021-03-26 2023-01-17 Vyripharm Enterprises, Inc. Synthetic cannabinoid combination therapy compositions and methods for personalized and targeted therapies including the treatment of infectious diseases
US20220305148A1 (en) * 2021-03-26 2022-09-29 Vyripharm Enterprises, Inc. Natural cannabinoid combination therapy compositions and methods for personalized and targeted therapies including the treatment of infectious diseases
US20220305145A1 (en) * 2021-03-26 2022-09-29 Vyripharm Enterprises, Inc. Compositions and methods for diagnosing viral infections including covid-19 and for infection severity monitoring as well as targeted detection of cytokine storm

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2530087A1 (en) * 2003-06-30 2005-02-03 Merck & Co., Inc. Radiolabeled cannabinoid-1 receptor modulators
JP2009534381A (ja) * 2006-04-19 2009-09-24 ボード オブ リージェンツ オブ ザ ユニバーシティ オブ テキサス システム 細胞画像化および治療のための組成物および方法
WO2009029727A1 (en) * 2007-08-28 2009-03-05 Vanderbilt University Cannabinoid receptor targeted agent
US20120288442A1 (en) * 2011-05-11 2012-11-15 Atomic Energy Council-Institute Of Nuclear Energy Research Nuclear Imaging Method Using Molecular Target Detection Agent for Liver Fibrosis
EP2992880A1 (de) * 2014-09-04 2016-03-09 Fundació Institut de Recerca de l'Hospital de la Santa Creu l Sant Pau Verwendung von Hämoxygenase-1-Induktoren und Cannabinoid-2-Rezeptor oder Delta-Opiod-Rezeptoragonisten bei Entzündungsschmerz
GB201417067D0 (en) * 2014-09-26 2014-11-12 South African Nuclear Energy Radiopharmaceutical conjugate

Also Published As

Publication number Publication date
JP2020527589A (ja) 2020-09-10
EA202090116A1 (ru) 2020-05-14
WO2019018536A1 (en) 2019-01-24
IL272060A (en) 2020-03-31
AU2018302155A1 (en) 2020-02-06
CN111065391A (zh) 2020-04-24
CA3070538A1 (en) 2019-01-24
MX2020000673A (es) 2020-07-29
EP3654971A1 (de) 2020-05-27
EP3654971A4 (de) 2021-04-21
AU2018302155B2 (en) 2022-09-15

Similar Documents

Publication Publication Date Title
AU2018302155B2 (en) Compositions containing cannabinoid analog conjugates and methods of use
JP6946342B2 (ja) エバンスブルー誘導体の化学的コンジュゲート、ならびに放射線治療剤およびイメージング剤としてのそれらの使用
Muller Folate based radiopharmaceuticals for imaging and therapy of cancer and inflammation
KR100784120B1 (ko) 에틸렌디시스테인(ｅｃ)-약물 접합체
KR102017324B1 (ko) 신규한 asm 활성 직접 억제 화합물 2-아미노-2-(1,2,3-트리아졸-4-일)프로판-1,3-디올 유도체 및 이의 용도
JP7097436B2 (ja) エバンスブルー誘導体の化学的コンジュゲートおよびそれらの放射線治療剤および造影剤としての使用
EP3755321A1 (de) Chemische konjugate von evans-blau-derivaten und deren verwendung als strahlentherapie- und bildgebungsmittel zum targeting von prostatakrebs
US11707539B2 (en) FAP-targeted radiopharmaceuticals and imaging agents, and uses related thereto
KR20100121530A (ko) 관류 영상화를 포함하는 용도를 위한 조영제
Kawamura et al. Synthesis and evaluation of [11 C] XR9576 to assess the function of drug efflux transporters using PET
Grimberg et al. Monitoring of tumor response to chemotherapy in vivo by a novel small-molecule detector of apoptosis
WO2016040458A2 (en) Pet probes of radiofluorinated carboximidamides for ido-targeted imaging
JP2024028840A (ja) シールド剤およびそれらの使用
CN109789227B (zh) 用于癌症成像和疗法的放射性磷脂金属螯合物
Kwon et al. Novel multifunctional 18F-labelled PET tracer with prostate-specific membrane antigen-targeting and hypoxia-sensitive moieties
Naguib et al. Synthesis, characterization, and in vitro and in vivo evaluations of 4-(N)-Docosahexaenoyl 2′, 2′-Difluorodeoxycytidine with potent and broad-spectrum antitumor activity
Teper et al. The effect of 5-aminolevulinic acid and its derivatives on protoporphyrin IX accumulation and apoptotic cell death in castrate-resistant prostate cancer cells
Mann et al. Receptor mapping using methoxy phenyl piperazine derivative: Preclinical PET imaging
AU2019225154B2 (en) Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents for targeting prostate cancer
US20240207292A1 (en) Boronic acid compounds, compositions and methods
Savoy Modular Smart Molecules for Targeted Drug Delivery
CN118591549A (zh) 碳酸酐酶ix配位体
AU2015200027B2 (en) Contrast agents for applications including perfusion imaging
KR20240133798A (ko) 탄산 무수화효소 ix 리간드

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application